Latest Conference Content

Dinesh Kapur, MD, chair, OneCouncil, and managing partner, Eastern Connecticut Hematology and Oncology (ECHO), speaks on efforts made by by community oncology practices to improve minority representation in oncology clinical trials and implications of the COVID-19 pandemic ahead of the 2021 Community Oncology Conference.

At the 2021 Cholangiocarcinoma Foundation Annual Conference, experts discussed clinical trials in cholangiocarcinoma and the ways in which clinical trials overall can be made more available to patients.

Michael I. D'Angelica, MD, FACS, of Memorial Sloan Kettering Cancer Center, gives insight on genomic testing and its growing role in cholangiocarcinoma.

Funda Meric-Bernstam, MD, chair of the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center, discusses some of the key aspects of successful trials.

Last year, pemigatinib, the first targeted therapy in cholangiocarcinoma was approved for previously treated patients with FGFR2 fusions or rearrangements.

At the 2021 Cholangiocarcinoma Foundation Annual Conference, experts discussed guidelines and real-world data for the management of urgent symptoms in patients with cholangiocarcinoma who have biliary stents or drains.

Funda Meric-Bernstam, MD, co-chair of the 2021 Cholangiocarcinoma Foundation Annual Conference, gives her insight on immunotherapies in cholangiocarcinoma.

Michael I. D'Angelica, MD, FACS, of Memorial Sloan Kettering Cancer Center, discusses multidisciplinary care and why it is so important in hepatobiliary cancers.

Kathy Oubre, MS, chief operating officer, Pontchartrain Cancer Center, explores US adoption of biosimilars ahead of her panel discussion at the 2021 Community Oncology Conference, as well as what sessions she’s looking forward to attending.

On the first day of the Cholangiocarcinoma Foundation Annual Meeting, Elli Brimble, MS, MSc, Ciitizen’s head of Clinical Operations, offered insights from an ongoing study based on data provided by patients.

Discussions at the start of the 2021 Annual Cholangiocarcinoma Foundation Conference centered on challenges and advances made during the COVID-19 pandemic, and the potential of liver transplantation in cholangiocarcinoma.

Funda Meric-Bernstam, MD, co-chair of the 2021 Cholangiocarcinoma Foundation Annual Conference, gives her input on the importance of hearing from patients and advocates as well as physicians in discussions around cholangiocarcinoma treatment.

Al B. Benson, MD, FACP, FASCO, professor of medicine and director for Cooperative Groups at the Robert H. Lurie Comprehensive Cancer Center, stresses the importance of approaching difficult hepatobiliary cancer settings with a multifaceted care team.

Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance, highlights his questions for the keynote speakers of the 2021 Community Oncology Conference, and takeaways he hopes audience members gain from the sessions.

Ted Okon, MBA, executive director, Community Oncology Alliance (COA), speaks on the most significant challenges members encountered in the past year managing the COVID-19 pandemic ahead of the 2021 Community Oncology Conference.

Jeff Patton, MD, CEO, OneOncology, chairman of the board, Tennessee Oncology, discusses what audience members should expect from the Community Oncology Conference 2021 and sessions he is looking forward to.

At the National Comprehensive Cancer Network Annual Conference, Arlene O. Siefker-Radtke, MD, discussed immune checkpoint inhibitors and their potential in urothelial bladder cancer.

Updates to the NCCN Guidelines in multiple myeloma reflect recent trial results, giving clinicians and patients many choices.

A panel at the NCCN Virtual Annual Meeting finds that while primary care physicians and oncologists can share information, records may not be well integrated and in easy-to-use formats.

Penn Medicine's Stephen Schuster, MD, offers an overview of an eventful year in CAR T-cell therapy at the NCCN Virtual Annual Meeting.

A keynote session at the NCCN Virtual Annual Conference brought a panel of patient advocates and experts together for a timely and necessary discussion about strategies to reduce racial disparities in oncology.

During a session at the National Comprehensive Cancer Network (NCCN) annual virtual conference, the payer perspective and physician experiences with PRO systems in both the community and academic medical center settings took center stage.

Pharmacists from the Cleveland Clinic discuss the impact of payer dispensing requirements, known as white bagging and brown bagging, on oncology practices and on patients.

Amye J. Tevaarwerk, MD, director of the Survivorship Program at the University of Wisconsin Carbone Cancer Center, discussed the impact that cancer diagnosis and treatment can have on survivors when it comes to work.

During a session presented at the America’s Health Insurance Plans (AHIP) National Health Policy Conference, Michael Chernew, PhD, the director of Healthcare Markets and Regulation Lab at Harvard Medical School, and Mark McClellan, MD, PhD, founding director at Duke Margolis Center for Health Policy, discussed the potential for Medicare innovation and reforms in 2021 and beyond.

The $1.9 trillion spending package aimed at providing COVID-19 relief for those with low and middle incomes also represents the biggest investment in the exchange marketplaces created by the Affordable Care Act (ACA) since the landmark law was passed 11 years ago.

During a session presented at the America’s Health Insurance Plans National Health Policy Conference, experts laid out potential policy priorities for states in the wake of the COVID-19 pandemic.

In a session presented at America’s Health Insurance Plans (AHIP’s) National Health Policy Conference, federal health officials and health plan representatives highlighted successes of the country’s ongoing COVID-19 vaccine rollout, placing particular emphasis on the role equity plays in distribution.

An administrator in the Geisinger Cancer Institute discusses the rollout of ClinicalPath.

A panel at the Association of Community Cancer Centers discusses lessons from the year of COVID-19.